Biomarkers for osteoarthritis: Current status and future prospects

IF 4.5 2区医学 Q1 RHEUMATOLOGY

Best Practice & Research in Clinical Rheumatology Pub Date : 2023-06-01 DOI:10.1016/j.berh.2023.101852

Ali Mobasheri , Christian S. Thudium , Anne-Christine Bay-Jensen , Tazio Maleitzke , Sven Geissler , Georg N. Duda , Tobias Winkler

{"title":"Biomarkers for osteoarthritis: Current status and future prospects","authors":"Ali Mobasheri , Christian S. Thudium , Anne-Christine Bay-Jensen , Tazio Maleitzke , Sven Geissler , Georg N. Duda , Tobias Winkler","doi":"10.1016/j.berh.2023.101852","DOIUrl":null,"url":null,"abstract":"<div><p>Osteoarthritis (OA) is the most common form of arthritis globally and a major cause of pain, physical disability, and loss of economic productivity, with currently no causal treatment available. This review article focuses on current research on OA biomarkers and the potential for using biomarkers in future clinical practice and clinical trials of investigational drugs. We discuss how biomarkers, specifically soluble ones, have a long path to go before reaching clinical standards of care. We also discuss how biomarkers can help in phenotyping and subtyping to achieve enhanced stratification and move toward better-designed clinical trials. We also describe how biomarkers can be used for molecular endotyping and for determining the clinical outcomes of investigational cell-based therapies. Biomarkers have the potential to be developed as surrogate end points in clinical trials and help private-public consortia and the biotechnology and pharmaceutical industries develop more effective and targeted personalized treatments and enhance clinical care for patients with OA.</p></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"37 2","pages":"Article 101852"},"PeriodicalIF":4.5000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521694223000384/pdfft?md5=1b5ed7f5b7c4f44b66381d1ba9c0667f&pid=1-s2.0-S1521694223000384-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research in Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521694223000384","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Osteoarthritis (OA) is the most common form of arthritis globally and a major cause of pain, physical disability, and loss of economic productivity, with currently no causal treatment available. This review article focuses on current research on OA biomarkers and the potential for using biomarkers in future clinical practice and clinical trials of investigational drugs. We discuss how biomarkers, specifically soluble ones, have a long path to go before reaching clinical standards of care. We also discuss how biomarkers can help in phenotyping and subtyping to achieve enhanced stratification and move toward better-designed clinical trials. We also describe how biomarkers can be used for molecular endotyping and for determining the clinical outcomes of investigational cell-based therapies. Biomarkers have the potential to be developed as surrogate end points in clinical trials and help private-public consortia and the biotechnology and pharmaceutical industries develop more effective and targeted personalized treatments and enhance clinical care for patients with OA.

查看原文本刊更多论文

骨关节炎的生物标志物：现状与前景。

骨关节炎（OA）是全球最常见的关节炎，也是造成疼痛、身体残疾和经济生产力损失的主要原因，目前尚无因果治疗方法。这篇综述文章重点介绍了目前有关 OA 生物标志物的研究，以及在未来临床实践和研究药物临床试验中使用生物标志物的潜力。我们讨论了生物标志物（尤其是可溶性生物标志物）在达到临床治疗标准之前还有很长的路要走。我们还讨论了生物标记物如何帮助进行表型和亚型分析，以加强分层，并向设计更佳的临床试验迈进。我们还介绍了生物标记物如何用于分子内分型和确定研究性细胞疗法的临床结果。生物标记物有可能被开发为临床试验的替代终点，帮助公私联合体以及生物技术和制药行业开发更有效、更有针对性的个性化治疗方法，并加强对 OA 患者的临床护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Best Practice & Research in Clinical Rheumatology 医学-风湿病学

CiteScore

9.40

自引率

0.00%

发文量

审稿时长

27 days

期刊介绍： Evidence-based updates of best clinical practice across the spectrum of musculoskeletal conditions. Best Practice & Research: Clinical Rheumatology keeps the clinician or trainee informed of the latest developments and current recommended practice in the rapidly advancing fields of musculoskeletal conditions and science. The series provides a continuous update of current clinical practice. It is a topical serial publication that covers the spectrum of musculoskeletal conditions in a 4-year cycle. Each topic-based issue contains around 200 pages of practical, evidence-based review articles, which integrate the results from the latest original research with current clinical practice and thinking to provide a continuous update. Each issue follows a problem-orientated approach that focuses on the key questions to be addressed, clearly defining what is known and not known. The review articles seek to address the clinical issues of diagnosis, treatment and patient management. Management is described in practical terms so that it can be applied to the individual patient. The serial is aimed at the physician in both practice and training.